Date: 27-Jul-2019

PureTech acquires LYT-100 to treat lymphedema

The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies and was observed to be well tolerated with a favourable pharmacokinetic profile to support twice daily oral dosing. The oral, small molecule candidate expands PureTechís internal R&D pipeline and continues its progress in developing new medicines based on insights into the lymphatic system and local modulation of the immune system for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.